Health & Environmental Research Online (HERO)


Print Feedback Export to File
2733182 
Journal Article 
Treatment of hypercholesterolemia with pantethine and fenofibrate: open randomized study on 43 subjects 
Cattin, L; Da Col, PG; Fonda, M; Mameli, MG; Feruglio, GA; Et al 
1985 
Yes 
Current Therapeutic Research
ISSN: 0011-393X 
IPA/86/679061 
Ther 
REF 33 
1985 
English 
IPA COPYRIGHT: ASHP The efficacy and tolerability of oral pantethine (I), 300 mg thrice daily, and fenofibrate (II), 100 mg thrice daily, both in capsule form, were compared in 43 subjects (aged 40-59 yr) for the treatment of hypercholesterolemia. The mean percentage decrease of LDL-C was about 20% at the 4th month for both I and II. Serum apoprotein B dropped equally in both groups. HDL-C remained unchanged in both groups, whereas apo A-I tended to increase with both compounds. Only II led to a significant increase of apo A-II at about 13% and 20% on the 2nd and 4th month, respectively. Similar results were present in type IIb subjects except for a more pronounced hypotriglyceridemic effect by II. Minor side effects were observed during the trial. Loss of libido occurred in one case at the 4th month of II therapy.